G Livingston1, A E Walker, C L E Katona, C Cooper. 1. Department of Mental Health Sciences, University College London, Holborn Union Building, Archway Campus, Highgate Hill, London N19 5LW, UK. g.livingston@ucl.ac.uk
Abstract
OBJECTIVE: To investigate in a longitudinal cohort of people with Alzheimer's disease whether taking antipsychotics is associated with more rapid cognitive deterioration. METHOD: From a sample of 224 people with Alzheimer's disease recruited as epidemiologically representative, those taking antipsychotic drugs for more than 6 months were compared with those who were not, in terms of change in three measures of cognition. The effects of potential mediators and confounders (demographic factors, neuropsychiatric symptoms, cognitive severity and cholinesterase inhibitors) were also examined. RESULTS: No significant difference was observed in cognitive decline between those taking antipsychotics (atypical or any) and others on any measure of cognition. The only predictor of more cognitive decline was greater baseline cognitive severity (B = 3.3, 95% confidence interval 0.6 to 6.1, t = 2.4, p<0.05). Although mortality was higher in those treated with antipsychotics, this reflected their greater age and severity of dementia. The results were the same when the whole cohort was included rather than the select group with potential to change who had been taking antipsychotics continuously. CONCLUSIONS: In this, the first cohort study investigating the effects of atypical antipsychotics on cognitive outcome in Alzheimer's disease, those taking antipsychotics were no more likely to decline cognitively over 6 months. Although clinicians should remain cautious when prescribing antipsychotic drugs to people with Alzheimer's disease, any increase in cognitive deterioration is not of the magnitude previously reported. There is a need for cohort studies that follow up patients from first prescription in clinical practice for a period of months rather than weeks to determine "real-life" risks and benefits.
OBJECTIVE: To investigate in a longitudinal cohort of people with Alzheimer's disease whether taking antipsychotics is associated with more rapid cognitive deterioration. METHOD: From a sample of 224 people with Alzheimer's disease recruited as epidemiologically representative, those taking antipsychotic drugs for more than 6 months were compared with those who were not, in terms of change in three measures of cognition. The effects of potential mediators and confounders (demographic factors, neuropsychiatric symptoms, cognitive severity and cholinesterase inhibitors) were also examined. RESULTS: No significant difference was observed in cognitive decline between those taking antipsychotics (atypical or any) and others on any measure of cognition. The only predictor of more cognitive decline was greater baseline cognitive severity (B = 3.3, 95% confidence interval 0.6 to 6.1, t = 2.4, p<0.05). Although mortality was higher in those treated with antipsychotics, this reflected their greater age and severity of dementia. The results were the same when the whole cohort was included rather than the select group with potential to change who had been taking antipsychotics continuously. CONCLUSIONS: In this, the first cohort study investigating the effects of atypical antipsychotics on cognitive outcome in Alzheimer's disease, those taking antipsychotics were no more likely to decline cognitively over 6 months. Although clinicians should remain cautious when prescribing antipsychotic drugs to people with Alzheimer's disease, any increase in cognitive deterioration is not of the magnitude previously reported. There is a need for cohort studies that follow up patients from first prescription in clinical practice for a period of months rather than weeks to determine "real-life" risks and benefits.
Authors: J S Paulsen; D P Salmon; L J Thal; R Romero; C Weisstein-Jenkins; D Galasko; C R Hofstetter; R Thomas; I Grant; D V Jeste Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: J S Street; W S Clark; D L Kadam; S J Mitan; B E Juliar; P D Feldman; A Breier Journal: Int J Geriatr Psychiatry Date: 2001-12 Impact factor: 3.485
Authors: L S Schneider; P N Tariot; C G Lyketsos; K S Dagerman; K L Davis; S Davis; J K Hsiao; D V Jeste; I R Katz; J T Olin; B G Pollock; P V Rabins; R A Rosenheck; G W Small; B Lebowitz; J A Lieberman Journal: Am J Geriatr Psychiatry Date: 2001 Impact factor: 4.105
Authors: Peter Paul De Deyn; Manuel Martín Carrasco; Walter Deberdt; Claude Jeandel; Donald P Hay; Peter D Feldman; Carrie A Young; Deborah L Lehman; Alan Breier Journal: Int J Geriatr Psychiatry Date: 2004-02 Impact factor: 3.485
Authors: Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman Journal: J Clin Psychiatry Date: 2003-02 Impact factor: 4.384
Authors: P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz Journal: Int J Geriatr Psychiatry Date: 2012-02-29 Impact factor: 3.485
Authors: Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2012-12 Impact factor: 4.105
Authors: Tamara G Fong; Michael A Fearing; Richard N Jones; Peilin Shi; Edward R Marcantonio; James L Rudolph; Frances M Yang; Dan K Kiely; Sharon K Inouye Journal: Alzheimers Dement Date: 2009-07-31 Impact factor: 21.566
Authors: Juha Puustinen; Janne Nurminen; Tero Vahlberg; Alan Lyles; Raimo Isoaho; Ismo Räihä; Sirkka-Liisa Kivelä Journal: Dement Geriatr Cogn Dis Extra Date: 2012-03-16
Authors: Esther S Oh; Paul B Rosenberg; Gail B Rattinger; Elizabeth A Stuart; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos Journal: J Am Geriatr Soc Date: 2020-12-31 Impact factor: 5.562
Authors: João Pedro Aguiar; Catarina Bernardo; João Gama Marques; Hubert Leufkens; Filipa Alves da Costa Journal: Front Psychiatry Date: 2020-10-30 Impact factor: 4.157